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Figure S1. Antibodies isolated from a SHIVAD8 infected rhesus macaque. A, FACS plots 
show the gating strategy used to isolate single germinal center B cells that bind to YU2 gp140-F 
and BG505 SOSIP from a lymph node sample collected from the elite neutralizer macaque 
CE8J. The sorted population of B cells is highlighted in red. B, Pie chart shows the clonal 
analysis of antibodies cloned from macaque CE8J. Expanded clones are represented in colored 
slices while singles are shown in white. The number of analyzed sequences is shown in the 
middle of the pie chart. C, Graph shows the number of nucleotide mutations in the VH, VL and 
VK genes of the antibodies shown in B. D, Length of CDRH3 for antibodies shown in B and C. 
The red dot corresponds to Ab 1485. E, Neutralization activity of Ab1538, Ab1542 and Ab1485 
determined in TZM-bl assays against a panel of 7 tier 1B and tier 2 pseudoviruses. 
 
Figure S2. Cryo-EM data processing and validation. (A) Representative micrograph and 2D 
class averages shown for Ab1485-BG505-8ANC195 complex data. (B) Angular distribution, (C) 
Gold-standard Fourier shell correlation plot, with dashed lines showing resolutions at 0.5 and 
0.143. (D) Local resolution as determined by ResMap depicted on side and top views of 
reconstructed volume. (E) Representative density contoured at 3 sigma for different regions of 
the complex 
 
Figure S3. Binding assays and structural comparison to V1//V3 antibodies raised in 
animals. (A-C). SPR sensorgrams for binding of Ab1485 Fab to immobilized BG505 (A), RC1 
(B), or RC1-glycan KO 324GAIA327 (C). Sensorgrams traces are shown in colors; the fits to a 1:1 
binding model are shown in black. (D) Comparison of Ab1485 (purple shades) Env binding 
orientation to antibodies 874NHP (PDB: 6ORN; orange), 897NHP (PDB: 6ORO; green), and 
43A2rabbit (PDB:6VO0; blue). Comparison with the predominant V1/V3 binding orientation 
observed after repeated challenge with SHIVBG505 is also shown (modeled Fab (olive) based on 
cryo-EM density (EMD-20396).  
 
 
Figure S4. Characterization of Ab1485. A, ELISA graphs showing binding of Ab1485 to 
lipopolysaccharide (LPS), Keyhole limpet hemocyanin (KLH), Insulin, single stranded DNA 
(ssDNA) and double stranded DNA (dsDNA). Antibody ED38(75, 76)  and antibody 
mGO53(75)were used as positive and negative controls respectively. B, Graph shows the 
antibody concentrations of Ab1485-macaque-LS and the control 10-1074 in the serum of mice 
that carry a null mutation for the mouse neonatal Fc receptor (FcRn) and a transgene for the 
human FcRn at different time points after intravenous infusion of the antibodies.	
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